Trastuzumab deruxtecan, already used in to treat patients with breast, ... The ADC mechanism of delivering therapy “right to the source” yielded encouraging results aside from pancreatic cancer.

Fam-trastuzumab deruxtecan (T-DXd) is an anti-HER2 ADC on the basis of an exatecan derivative, 14 and sacituzumab govitecan (SG) is an anti-TROP2 ADC that uses SN-38 (the active metabolite of ...

FDA has granted priority review status to trastuzumab deruxtecan (Enhertu) for the treatment of adults with HER2-positive ... (IHC) 3+ solid tumors. 1 The deadline for FDA action is May 30, 2024. 2.

SAN ANTONIO — Fam-trastuzumab deruxtecan-nxki induced encouraging response rates among certain patients with early breast cancer, according to findings presented at San Antonio Breast Cancer ...

Trastuzumab deruxtecan-THP was associated with a statistically significant and clinically meaningful improvement in pathologic complete response rate vs standard of care. The DESTINY-Breast11 ...

WILMINGTON, Del., October 01, 2024--AstraZeneca and Daiichi Sankyo’s supplemental Biologics License Application (sBLA) for ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been accepted and ...

With ENHERTU (fam-trastuzumab deruxtecan-nxki), a HER2-directed antibody drug conjugate (ADC), AstraZeneca and Daiichi Sankyo are aiming to improve outcomes in previously treated HER2-positive and ...

ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival vs. THP as 1st-line ...

In patients with HER2-ultralow expression, trastuzumab deruxtecan reduced the risk of disease progression or death by 22% compared with chemotherapy (HR, 0.78 [95% CI, 0.50-1.21); median PFS was ...

Health Canada granted a Notice of Compliance with conditions (NOC/c) for ENHERTU (trastuzumab deruxtecan) on January 17, 2025, for the treatment of adult patients with unresectable, locally ...